AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections
Completed
- Conditions
- Community Acquired Pneumonia (CAP)Complicated Skin and Skin Structures Infections (cSSSI)
- First Posted Date
- 2011-02-10
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4035
- Registration Number
- NCT01293435
- Locations
- 🇬🇧
Research Site, Winchester, United Kingdom
Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India
Completed
- Conditions
- DyslipidemiaType 2 Diabetes Mellitus
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5400
- Registration Number
- NCT01292018
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
Phase 2
Terminated
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2012-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 145
- Registration Number
- NCT01288079
- Locations
- 🇯🇵
Research Site, Kumamoto, Japan
Asthma in Children
Completed
- Conditions
- Asthma
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 283
- Registration Number
- NCT01286532
- Locations
- 🇷🇺
Research site, Volgograd, Russian Federation
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5472
- Registration Number
- NCT01285180
- Locations
- 🇩🇪
Nycomed Deutschland GmbH, Übach-Palenberg, Germany
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3645
- Registration Number
- NCT01285167
- Locations
- 🇩🇪
Nycomed Deutschland GmbH, Überlingen, Germany
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
Completed
- Conditions
- Prostatic Cancer
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2012-12-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 197
- Registration Number
- NCT01284608
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C] AZD8931
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT01284595
- Locations
- 🇬🇧
Research Site, London, United Kingdom
AZD2115 Single Ascending Dose Study
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseLung Disease Causing Persistent Narrowing of the Airways
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 96
- Registration Number
- NCT01283984
- Locations
- 🇬🇧
Research Site, London, UK, United Kingdom
Multicentre Retrospective Study to Understand Anti-thrombotic Treatment Patterns and Outcomes of Acute Coronary Syndrome (ACS) Patients
Completed
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT01280630
- Locations
- 🇮🇳
Research Site, Chennai, Tamil Nadu, India